A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF) [clinicaltrials:NCT00340314]

Bio2RDF identifier

NCT00340314

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00340314

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00340314

acronym [clinicaltrials_vocabulary:acronym]

APAF2

http://www.w3.org/2001/XMLSchema#string

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:0cc1843f599095dc478a931bdb1e8d31

brief summary [clinicaltrials_vocabulary:brief-summary]

Background: Circumferen ...... randomized controlled trial.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Trial of Circumferential Pul ...... ysmal Atrial Fibrillation (AF)

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:3dfbf451d1fe08ad8e6f86b891956bdd]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:046fb72db7fe07dc3c70c77bcff3b012]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:061debe3297c2f87fd496d0e21ed868c]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:09cc041ff5808b3b9cc16bd684c9beda]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:0b000ed317b45e9a60b069f2107fcdd2]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:129390863224cc76a237b338591672f2]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:29c3d39cd016051b89e4f7d009092866]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:58c8522596df44e4d489f700b673b773]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:6003de2e0beefd0bfd8325689b79024e]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:936aeddcf254f75b08fcf77515df1b78]

The primary end point was freedom from recurrent atrial tachyarrhythmias ([AT], both AF and regular atrial tachycardia) during a 12 and 48 months follow-up . The first analysis was scheduled to be performed after the last enrolled patient complete. [clinicaltrials_resource:9b9abe26a444e4aaff13ec8f961efcb8]

completion date [clinicaltrials_vocabulary:completion-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

Antiarrhythmic drug the ...... nefit is extended to 4 years.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00340314 [clinicaltrials_resource:c84de764c091553f70a8cd62d6540d1d]

enrollment [clinicaltrials_vocabulary:enrollment]

198

http://www.w3.org/2001/XMLSchema#integer

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2006-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Antiarrhythmic Drug Therapy [clinicaltrials_resource:83b0badddc82717fa23564855b2fff29]

Circumferential Pulmonary Vein Ablation [clinicaltrials_resource:f597c9ff9ca61c42ac4ef2ec5b751526]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Anti-Arrhythmia Agents [clinicaltrials_resource:d221c35e3b6d4d778a1bb0bde05a8174]

keyword [clinicaltrials_vocabulary:keyword]

atrial fibrillation

http://www.w3.org/2001/XMLSchema#string

paroxysmal

http://www.w3.org/2001/XMLSchema#string

symptomatic

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2010-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

IRCCS San Raffaele [clinicaltrials_resource:c85c50d6d73775b4c13a86d0979077b2]

link [clinicaltrials_vocabulary:link]

Our Departement Web site [clinicaltrials_resource:7d4d97a43243369d95072486a52735a8]

San Raffaele Web site [clinicaltrials_resource:8f4526c9794ffb349586eb37098fd810]

location [clinicaltrials_vocabulary:location]

San Raffaele University Hospital [clinicaltrials_resource:8197d6a46bd0b7b497f538940691e1ef]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00340314

http://www.w3.org/2001/XMLSchema#string

official title [clinicaltrials_vocabulary:official-title]

A Controlled Randomized Trial ...... ial Fibrillation (APAF2) Trial

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

APAF/02

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Carlo Pappone, MD, PhD [clinicaltrials_resource:3d397f418a0ea47f681e1fec79e06e83]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Italy: National Monitoring Centre for Clinical Trials - Ministry of Health [clinicaltrials_resource:52311865d084ef1dae36e02d7d2119aa]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

source [clinicaltrials_vocabulary:source]

IRCCS San Raffaele [clinicaltrials_resource:c85c50d6d73775b4c13a86d0979077b2]

start date [clinicaltrials_vocabulary:start-date]

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00340314 study design [clinicaltrials_resource:e9a9de92c70463e4c1a76c6c2aba1fcd]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00340314

verification date [clinicaltrials_vocabulary:verification-date]

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00340314

http://www.w3.org/2001/XMLSchema#string

title

A Trial of Circumferential Pul ...... ysmal Atrial Fibrillation (AF)

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Trial of Circumferential Pul ...... ) [clinicaltrials:NCT00340314]

@en